Literature DB >> 30742944

Knock-down of oncohistone H3F3A-G34W counteracts the neoplastic phenotype of giant cell tumor of bone derived stromal cells.

J Fellenberg1, H Sähr2, D Mancarella3, C Plass3, A M Lindroth4, F Westhauser2, B Lehner2, V Ewerbeck2.   

Abstract

Giant cell tumors of bone (GCTB) are semi-malignant tumors associated with extensive osteolytic defects and massive bone destructions. They display a locally aggressive behavior and a very high recurrence rate. Recently, a single mutation has been identified in GCTB affecting the H3F3A gene coding for the histone variant H3.3 (H3.3-G34W). The aim of this study was to investigate whether H3.3-G34W is sufficient to drive tumorigenesis in GCTB. Initially, we confirmed the high frequency of this mutation in 94% of 84 analyzed tissue samples. Using a siRNA based approach we could selectively knockdown H3.3-G34W in primary neoplastic stromal cells isolated from tumor tissue (GCTSC). H3.3-G34W knockdown caused a significant inhibition of cell proliferation, migration and colony formation capacity in vitro. Xenotransplantation of GCTSCs onto the chorioallantoic membrane of fertilized chicken eggs further demonstrated a significant impact of H3.3-G34W knockdown on tumor engraftment and growth in vivo. Our data indicate that H3.3-G34W is sufficient to drive tumorigenesis in GCTB. Apart from the application of H3.3-G34W screening as diagnostic tool, our data suggest that H3.3-G4W represents a promising target for the development of new GCTB therapies.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CAM assay; Giant cell tumor of bone; H3.3-G34W; Histone; Neoplastic transformation

Mesh:

Substances:

Year:  2019        PMID: 30742944     DOI: 10.1016/j.canlet.2019.02.001

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  9 in total

Review 1.  Solid tumours hijack the histone variant network.

Authors:  Flávia G Ghiraldini; Dan Filipescu; Emily Bernstein
Journal:  Nat Rev Cancer       Date:  2021-02-10       Impact factor: 60.716

2.  When primary hyperparathyroidism comes as good news.

Authors:  Daniela Gallo; Sara Rosetti; Ilaria Marcon; Elisabetta Armiraglio; Antonina Parafioriti; Graziella Pinotti; Giuseppe Perrucchini; Bohdan Patera; Linda Gentile; Maria Laura Tanda; Luigi Bartalena; Eliana Piantanida
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2020-06-04

Review 3.  Mutation-driven epigenetic alterations as a defining hallmark of central cartilaginous tumours, giant cell tumour of bone and chondroblastoma.

Authors:  Sanne Venneker; Karoly Szuhai; Pancras C W Hogendoorn; Judith V M G Bovée
Journal:  Virchows Arch       Date:  2019-11-14       Impact factor: 4.064

Review 4.  Histone Variant H3.3 Mutations in Defining the Chromatin Function in Mammals.

Authors:  Matteo Trovato; Vibha Patil; Maja Gehre; Kyung Min Noh
Journal:  Cells       Date:  2020-12-18       Impact factor: 6.600

5.  Nuclear β-catenin translocation plays a key role in osteoblast differentiation of giant cell tumor of bone.

Authors:  Atsushi Kimura; Yu Toda; Yoshihiro Matsumoto; Hidetaka Yamamoto; Kenichiro Yahiro; Eijiro Shimada; Masaya Kanahori; Ryunosuke Oyama; Suguru Fukushima; Makoto Nakagawa; Nokitaka Setsu; Makoto Endo; Toshifumi Fujiwara; Tomoya Matsunobu; Yoshinao Oda; Yasuharu Nakashima
Journal:  Sci Rep       Date:  2022-08-04       Impact factor: 4.996

Review 6.  Metastatic giant cell tumour of bone: a narrative review of management options and approaches.

Authors:  Ruiwen Xu; Peter F M Choong
Journal:  ANZ J Surg       Date:  2022-02-10       Impact factor: 2.025

7.  Histone Deacetylase Inhibitors as a Therapeutic Strategy to Eliminate Neoplastic "Stromal" Cells from Giant Cell Tumors of Bone.

Authors:  Sanne Venneker; Robin van Eenige; Alwine B Kruisselbrink; Ieva Palubeckaitė; Alice E Taliento; Inge H Briaire-de Bruijn; Pancras C W Hogendoorn; Michiel A J van de Sande; Hans Gelderblom; Hailiang Mei; Judith V M G Bovée; Karoly Szuhai
Journal:  Cancers (Basel)       Date:  2022-09-27       Impact factor: 6.575

8.  Establishment and characterization of novel patient-derived cell lines from giant cell tumor of bone.

Authors:  Yuki Yoshimatsu; Rei Noguchi; Ryuto Tsuchiya; Takuya Ono; Yooksil Sin; Sei Akane; Jun Sugaya; Tomoaki Mori; Suguru Fukushima; Akihiko Yoshida; Akira Kawai; Tadashi Kondo
Journal:  Hum Cell       Date:  2021-07-24       Impact factor: 4.374

9.  H3.3 G34W Promotes Growth and Impedes Differentiation of Osteoblast-Like Mesenchymal Progenitors in Giant Cell Tumor of Bone.

Authors:  Sima Khazaei; Nicolas De Jay; Shriya Deshmukh; Liam D Hendrikse; Wajih Jawhar; Carol C L Chen; Leonie G Mikael; Damien Faury; Dylan M Marchione; Joel Lanoix; Éric Bonneil; Takeaki Ishii; Siddhant U Jain; Kateryna Rossokhata; Tianna S Sihota; Robert Eveleigh; Véronique Lisi; Ashot S Harutyunyan; Sungmi Jung; Jason Karamchandani; Brendan C Dickson; Robert Turcotte; Jay S Wunder; Pierre Thibault; Peter W Lewis; Benjamin A Garcia; Stephen C Mack; Michael D Taylor; Livia Garzia; Claudia L Kleinman; Nada Jabado
Journal:  Cancer Discov       Date:  2020-09-23       Impact factor: 38.272

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.